Skip to content
  • KOSPI 2591.86 -42.84 -1.63%
  • KOSDAQ 841.91 -13.74 -1.61%
  • KOSPI200 352.58 -6.48 -1.80%
  • USD/KRW 1379 -1 -0.07%
  • JPY100/KRW 892.47 -0.07 -0.01%
  • EUR/KRW 1470.77 +1.76 +0.12%
  • CNH/KRW 190.3 -0.09 -0.05%
View Market Snapshot
Management

Summary of Samsung's $200 billion investment plans

About $150 billion will be spent within South Korea, while another $50 billion will be invested overseas

By Aug 24, 2021 (Gmt+09:00)

3 Min read

Samsung Group said on Tuesday it will invest a combined 240 trillion won ($206 billion) investment over the next three years in its core businesses including semiconductors, displays and biopharmaceuticals.

180 trillion won ($154 billion) will be spent within South Korea, while 60 trillion won ($51 billion) will be invested overseas.

Below are the key points of Samsung’s investment plan: 

Memory Chips

• Widen the gap versus the competition by improving technological competence and price competitiveness.
• Expand investment in next-generation products such as DRAMs under 14 nm process and 200-stack or above layer NAND.
• In the memory segment, Samsung Electronics Co. will continue R&D and infrastructure investments in line with long-term market demands as opposed to short-term changes.  

Non-memory Chips
• Become the top maker in the world with timely development and deployment of advanced manufacturing processes
• Mass-produce chips under 3 nm process earlier than scheduled by developing new structures with the use of gate-all-around (GAA) transistor technologies.
• In the non-memory segment, Samsung will conduct early execution of the previously planned investments.

Contract Development Manufacturing & Biosimilars
• Samsung Biologics Co. and the group’s biosimilar unit Samsung Bioepis Co. will continue to expand investment in manufacturing facilities.
• Samsung Biologics, once its Plant 4 completes construction by 2023, will be the largest Contract Development Manufacturing Organization (CDMO) with an annual capacity of 620,000 liters, surpassing the runner-up Boehringer Ingelheim at 480,000 liters.
• Samsung Biologics will also build Plant 5 and Plant 6 to become the leading global hub for biopharmaceutical production.
• Samsung Biologics will enter new segments within the CDMO business including next-generation vaccines, cell therapies and DNA-based therapeutics.
• The biopharmaceutical sector will be the Samsung Group’s “next semiconductor business,” where the group holds a dominant position in the global market.

Next-Generation Communication Networks
• Samsung Electronics, the first company in the world to have deployed commercial 5G, will continue to lead its current leadership in networks to 6G and beyond.
• Samsung has set up a next-generation communications research center under Samsung Research, and also published a white paper on 6G communications.
• Samsung’s investment in the communication and networks sector will primarily center around the advancement and intellectualization of software technologies.
• Samsung will expand R&D investment in recruiting top talents in network virtualization and open radio access network (RAN).

AI & Robotics
• Samsung Research’s global AI centers located in key regions around the world will continue to develop new industry-applicable technologies.
• In robotics, Samsung will secure core technologies and diversify form factors to accelerate the expansion of robot usage in our daily lives. Supercomputers will be used to improve the level of robotic technologies.

Display & Batteries
• In the display sector, Samsung will commercialize next-generation OLED and quantum dot (QD) displays.
• In batteries, Samsung will develop high-density batteries that have higher energy capacity as well as all-solid-state batteries.

Write to Hyung-suk Song at click@hankyung.com
Daniel Cho edited this article.
Comment 0
0/300